GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » EBITDA Margin %

Serina Therapeutics (Serina Therapeutics) EBITDA Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Serina Therapeutics's EBITDA for the six months ended in Mar. 2024 was $-9.31 Mil. Serina Therapeutics's Revenue for the six months ended in Mar. 2024 was $0.00 Mil. Therefore, Serina Therapeutics's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.

Serina Therapeutics EBITDA Margin % Historical Data

The historical data trend for Serina Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics EBITDA Margin % Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22
EBITDA Margin %
-40.41 -521.00

Serina Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Mar24
EBITDA Margin % - -276.40 - - -

Competitive Comparison of Serina Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Serina Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Serina Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's EBITDA Margin % falls into.


Serina Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Serina Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-2.605/0.5
=-521.00 %

Serina Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-9.313/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics  (AMEX:SER) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Serina Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics (Serina Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » EBITDA Margin %
Comparable Companies
Traded in Other Exchanges
2BO:Germany
Address
601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Website
https://www.serinatherapeutics.com
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines

From GuruFocus

Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse� for Advanced Parkinson's Disease

By Marketwired • 05-15-2024